Polymorphisms of MLH1 in benign prostatic hyperplasia and sporadic prostate cancer

Mismatch repair is one of several DNA repair pathways of which defects may lead to cancer. We hypothesize that polymorphisms of the MLH1 gene can be a risk factor for benign prostatic hyperplasia (BPH) and prostate cancer. The genetic distribution of MLH1 polymorphisms that lead to amino acid change...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2009-06, Vol.383 (4), p.440-444
Main Authors: Tanaka, Yuichiro, Zaman, Mohd S., Majid, Shahana, Liu, Jan, Kawakami, Kazumori, Shiina, Hiroaki, Tokizane, Takashi, Dahiya, Angela V., Sen, Saunak, Nakajima, Koichi
Format: Article
Language:English
Subjects:
Adaptor Proteins, Signal Transducing - genetics
Aged
Amino Acid Substitution
Cancer
Genetic Predisposition to Disease
Humans
Male
MLH1
MutL Protein Homolog 1
Nuclear Proteins - genetics
Polymorphism
Polymorphism, Genetic
Prostate
Prostatic Hyperplasia - genetics
Prostatic Neoplasms - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mismatch repair is one of several DNA repair pathways of which defects may lead to cancer. We hypothesize that polymorphisms of the MLH1 gene can be a risk factor for benign prostatic hyperplasia (BPH) and prostate cancer. The genetic distribution of MLH1 polymorphisms that lead to amino acid changes at codons 132, 219, 384, and 723 were analyzed in BPH and sporadic prostate cancer patients, and compared to healthy controls from an Asian population. These experiments demonstrate a protective role for the codon 384 variant allele against prostate cancer ( P = 0.031) but not BPH when compared to normal controls and furthermore, an inverse association was observed with stage ( P = 0.074) and grade ( P = 0.056) of cancer. This is the first report that demonstrates a protective effect for the race-related MLH1 polymorphism at codon 384 against prostate cancer and these results are important in understanding their role in this disease.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2009.04.025